Average cost of multi drug-resistant tuberculosis treatment in Philippines
Philippines: Average cost of multi drug-resistant tuberculosis treatment was 310 constant 2022 US$ in 2024. ◆ Volatile
Average cost of multi drug-resistant tuberculosis treatment in Philippines, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of multi drug-resistant tuberculosis treatment in Philippines is 310 constant 2022 US$, measured in 2024. That is the lowest value across all 8 years on record.
That represents a change of down 28.1% on the previous year and down 95.3% over ten years.
Philippines ranks 89th of 92 countries on this measure, in the bottom quarter.
Average cost of multi drug-resistant tuberculosis treatment in Philippines, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 6,630 constant 2022 US$ | — |
| 2018 | 6,630 constant 2022 US$ | +0.0% |
| 2019 | 1,502 constant 2022 US$ | -77.3% |
| 2020 | 1,339 constant 2022 US$ | -10.9% |
| 2021 | 6.77 million constant 2022 US$ | +505689.4% |
| 2022 | 1,659 constant 2022 US$ | -100.0% |
| 2023 | 431 constant 2022 US$ | -74.0% |
| 2024 | 310 constant 2022 US$ | -28.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 4,921 constant 2022 US$ | 1,502 constant 2022 US$ | 6,630 constant 2022 US$ | 3 |
| 2020s | 1.36 million constant 2022 US$ | 310 constant 2022 US$ | 6.77 million constant 2022 US$ | 5 |
Countries ranked near Philippines
- 86 Benin 426 constant 2022 US$ compare
- 87 India 400 constant 2022 US$ compare
- 88 Sierra Leone 369 constant 2022 US$ compare
- 90 Tajikistan 257 constant 2022 US$ compare
- 91 Burkina Faso 159 constant 2022 US$ compare
- 92 Lesotho 81 constant 2022 US$ compare
More health data for Philippines
- Un projection of annual infant deaths, annual growth rate -1.24 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5317 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,456 deaths per 1,000 people (2090)
- Number of infants who die before age 1 7,006 deaths (2100)
- Population ages 0-14, female, annual growth rate -1.95 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.1327 units per person (2025)
- Population ages 0-14, male, annual growth rate -1.7 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.1387 units per person (2025)
Frequently asked questions
- What is average cost of multi drug-resistant tuberculosis treatment in Philippines?
- Average cost of multi drug-resistant tuberculosis treatment in Philippines was 310 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of multi drug-resistant tuberculosis treatment recorded in Philippines?
- The highest recorded value was 6.77 million constant 2022 US$ in 2021.
- What is the lowest average cost of multi drug-resistant tuberculosis treatment recorded in Philippines?
- The lowest recorded value was 310 constant 2022 US$ in 2024.
- How does Philippines rank for average cost of multi drug-resistant tuberculosis treatment?
- Philippines ranks 89th out of 92 countries with data for 2024.
- Is average cost of multi drug-resistant tuberculosis treatment rising or falling in Philippines?
- Over the last ten years it is down 95.3%. The long-run trend across the full record is volatile.
- Where does this Philippines data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of multi drug-resistant tuberculosis treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.